65,437 trials
Hemophilia A
Primary: Annualized Bleeding Rate (ABR) for Treated Bleeds — 38.2; 1.5; 1.3; 1.6 treated bleed rate per year — p=<0.0001
Nicotine Addiction · Drug Addiction · Drug Dependence
Primary: Number of Participants Who Remain Active Users of the Program — 365 Participants
Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 — 80; 69; 76; 72 Percentage of Participants
Healthy Volunteers
Primary: Time to Completion — 55.3; 54.5; 59.5 seconds to completion in post test
Chronic Hepatitis C · Genotype 1
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12) — 22.2; 16.1; 18.6; 23.3 percentage of participants
Schizophrenia
Primary: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score — -16.0; -22.8; -25.9 Units on a Scale — p=0.0029
Infections, Bacterial
Primary: Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of Plasma Gepotidacin for Part 1a — 16733; 17495; 18646…
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
Motor Activity
Primary: Change in Youth Physical Activity — 32.13; 36.47; 33.16; 36.50 minutes/day
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score — 2.59; 2.68; 2.52; -1.94 Score on Scale — p=<0.0001
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.13; 0.17; 0.16; 0.01 Z-score — p=0.7907
Myopia
Primary: Visual Acuity Using logMAR — -0.14; -0.13; -0.13; -0.14 logMAR
Immune Thrombocytopenic Purpura
Primary: Efficacy of Higher Double Doses of Rituxan and of Standard Dose of Rituxan + Cyclophosphamide, Vincristine, Prednisone — 8; 7; 1; 1 Participants
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Hereditary Angioedema Types I and II
Primary: Person-time Incidence Rates (Subject Based) — 0.01; 0.03; 0.00; 0.01 participants with events/year